Endocrinol Metab.  2017 Jun;32(2):274-280. 10.3803/EnM.2017.32.2.274.

Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes

• Han E
• Kim G
• Lee JY
• Lee YH
• Kim BS
• Lee BW
• Cha BS
• Kang ES

• KMID: 2384087
• DOI: http://doi.org/10.3803/EnM.2017.32.2.274

Abstract

BACKGROUND
Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes.
METHODS
We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was defined as a >3% reduction in eGFR in a 1-year period.
RESULTS
In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 to 78.8 mL/min/1.73 m² for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m² for rosuvastatin [P=0.001]). A more rapid eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7% vs. 38.6%, P=0.029). Multiple logistic regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors (odds ratio, 1.60; 95% confidence interval, 1.06 to 2.42).
CONCLUSION
These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.

Keyword

Atorvastatin calcium; Rosuvastatin calcium; Diabetes mellitus; Renal insufficiency, chronic

MeSH Terms

Asian Continental Ancestry Group
Atherosclerosis
Atorvastatin Calcium*
Diabetes Mellitus
Diabetic Nephropathies
Dyslipidemias
Glomerular Filtration Rate
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Logistic Models
Renal Insufficiency, Chronic
Rosuvastatin Calcium*
Atorvastatin Calcium
Rosuvastatin Calcium

Reference

1. Radhakrishnan J, Remuzzi G, Saran R, Williams DE, Rios-Burrows N, Powe N, et al. Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney Int. 2014; 86:246–250.

2. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. US renal data system 2010 annual data report. Am J Kidney Dis. 2011; 57:1 Suppl 1. A8e1–e526.

3. Park CW. Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J. 2014; 38:252–260.

4. Ahn JH, Yu JH, Ko SH, Kwon HS, Kim DJ, Kim JH, et al. Prevalence and determinants of diabetic nephropathy in Korea: Korea National Health and Nutrition Examination Survey. Diabetes Metab J. 2014; 38:109–119.

5. de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015; 3:181–190.

6. Kim SS, Kim JH, Kim IJ. Current challenges in diabetic nephropathy: early diagnosis and ways to improve outcomes. Endocrinol Metab (Seoul). 2016; 31:245–253.

7. Mulec H, Johnsen SA, Wiklund O, Bjorck S. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis. 1993; 22:196–201.

8. Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011; 5:41–48.

9. Moon BS, Kim J, Kim JH, Hyun YY, Park SE, Oh HG, et al. Eligibility for statin treatment in Korean subjects with reduced renal function: an observational study. Endocrinol Metab (Seoul). 2016; 31:402–409.

10. Koo BK. Statin for the primary prevention of cardiovascular disease in patients with diabetes mellitus. Diabetes Metab J. 2014; 38:32–34.

11. Campese VM, Park J. HMG-CoA reductase inhibitors and the kidney. Kidney Int. 2007; 71:1215–1222.

12. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009; 54:810–819.

13. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA. 2007; 297:1344–1353.

14. Savarese G, Musella F, Volpe M, Paneni F, Perrone-Filardi P. Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. Int J Cardiol. 2013; 167:2482–2489.

15. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007; 99:410–414.

16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150:604–612.

17. Yokoyama H, Kanno S, Takahashi S, Yamada D, Itoh H, Saito K, et al. Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension. Clin J Am Soc Nephrol. 2009; 4:1432–1440.

18. Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Larsen E, Ghali WA, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006; 69:2155–2161.

19. Meguro S, Tomita M, Kabeya Y, Katsuki T, Oikawa Y, Shimada A, et al. Factors associated with the decline of kidney function differ among eGFR strata in subjects with type 2 diabetes mellitus. Int J Endocrinol. 2012; 2012:687867.

20. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl. 1991; 31:S29–S34.

21. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int. 1990; 37:880–891.

22. Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000; 11:669–683.

23. Li C, Lim SW, Choi BS, Lee SH, Cha JH, Kim IS, et al. Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol. 2005; 25:611–620.

24. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia. 2003; 46:843–851.

25. Jandeleit-Dahm K, Cao Z, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl. 1999; 71:S31–S36.

26. Molnar AO, Coca SG, Devereaux PJ, Jain AK, Kitchlu A, Luo J, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol. 2011; 22:939–946.

27. Welten GM, Chonchol M, Schouten O, Hoeks S, Bax JJ, van Domburg RT, et al. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. Nephrol Dial Transplant. 2008; 23:3867–3873.

28. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006; 17:2006–2016.

29. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007; 2:1131–1139.

30. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ. 2013; 346:f880.

31. Kose E, An T, Kikkawa A, Matsumoto Y, Hayashi H. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. Biol Pharm Bull. 2014; 37:226–231.

32. Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol. 2005; 96(5A):11F–23F.

33. Takemoto M, Ishikawa T, Onishi S, Okabe E, Ishibashi R, He P, et al. Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia. Diabetes Res Clin Pract. 2013; 100:e26–e29.